TABLE 2

Characteristics of diabetes samples with allele frequencies for all three SNPs

Populationn (male/female)Age (years)BMI (kg/m2)Fasting plasma glucose (mmol/l)HbA1c (%)* or plasma glucose at 2-h OGTT (mmol/l)†Minor allele frequency
rs1044498 (Q)rs1799774 (delT)rs7754561 (G)
U.S. case/control
    Diabetes644/58263 ± 1133 ± 79.8 ± 3.08.0 ± 3.1*0.140.220.25
    NGT644/58261 ± 1027 ± 55.1 ± 0.9ND0.160.230.28
Poland case/control
    Diabetes422/58762 ± 1030 ± 58.9 ± 4.07.9 ± 1.3*0.130.190.22
    NGT422/58759 ± 726 ± 44.8 ± 1.2ND0.150.220.27
Scandinavia trios
    Probands168/15339 ± 927 ± 57.2 ± 2.68.5 ± 2.9†0.130.200.18
    Parents236/236
Sibships
    Diabetes/severe IGT sib280/32965 ± 1029 ± 59.3 ± 3.314.3 ± 5.6†0.160.220.21
    NGT sib275/30562 ± 1026 ± 35.4 ± 0.46.0 ± 1.1†0.120.190.20
Scandinavia case/control
    Diabetes/severe IGT252/21960 ± 1028 ± 59.8 ± 3.415.0 ± 5.3†0.140.190.19
    NGT254/21760 ± 1027 ± 46.2 ± 1.86.8 ± 2.8†0.130.210.20
Sweden case/control
    Diabetes/severe IGT267/24766 ± 1228 ± 49.6 ± 2.96.5 ± 1.5*0.150.160.18
    NGT267/24766 ± 1228 ± 45.5 ± 0.7ND0.160.170.19
Canada case/control
    Diabetes70/5753 ± 829 ± 56.4 ± 1.812.8 ± 2.1†0.130.170.24
    NGT70/5752 ± 829 ± 45.1 ± 0.66.1 ± 1.1†0.120.220.30
  • Data are means ± SD. Plasma glucose was measured at baseline (fasting) and 2 h after an oral glucose tolerance test (OGTT). “Severe IGT” was defined as an oral glucose tolerance test 2-h blood glucose ≥8.5 but <10.0 mmol/l. IGT, impaired glucose tolerance; ND, not determined; NGT, normal glucose tolerance.